Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial)

Abstract Background Apnoea of prematurity (AOP) is one of the most common diagnoses among preterm infants. AOP often leads to hypoxemia and bradycardia which are associated with an increased risk of death or disability. In addition to caffeine therapy and non-invasive respiratory support, doxapram m...

Full description

Bibliographic Details

Published in:	Trials
Main Authors:	Jarinda A. Poppe, Robert B. Flint, Anne Smits, Sten P. Willemsen, Kelly K. Storm, Debbie H. Nuytemans, Wes Onland, Marten J. Poley, Willem P. de Boode, Katherine Carkeek, Vincent Cassart, Luc Cornette, Peter H. Dijk, Marieke A. C. Hemels, Isabelle Hermans, Matthias C. Hütten, Dorottya Kelen, Ellen H. M. de Kort, André A. Kroon, Julie Lefevere, Katleen Plaskie, Breanne Stewart, Michiel Voeten, Mirjam M. van Weissenbruch, Olivia Williams, Inge A. Zonnenberg, Thierry Lacaze-Masmonteil, Arjan B.te Pas, Irwin K. M. Reiss, Anton H. van Kaam, Karel Allegaert, G. Jeroen Hutten, Sinno H. P. Simons
Format:	Article
Language:	English
Published:	BMC 2023-10-01
Subjects:	Doxapram Placebo Randomized controlled trial Preterm infants Apnoea of prematurity Efficacy and safety
Online Access:	https://doi.org/10.1186/s13063-023-07683-5